Responses
Oral Sessions
01. Cervical cancer
342 Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study
Compose a Response to This Article
Other responses
No responses have been published for this article.